Coherus SEC Filings

Coherus Oncology reported first quarter 2026 results showing early progress in its oncology transition. Net revenue from continuing operations was $12.3 million, up from $7.6 million a year earlier, driven by LOQTORZI net revenue of $11.8 million in the quarter.

GAAP net loss from continuing operations narrowed to $36.9 million, or $(0.27) per share, versus $47.4 million, or $(0.41) per share, with lower R&D and SG&A reflecting the 2025 exit from the biosimilar business. Non-GAAP net loss from continuing operations was $33.9 million, or $(0.25) per share. Cash, cash equivalents and marketable securities totaled $167.0 million as of March 31, 2026, while the company highlighted clinical progress for tagmokitug and casdozokitug alongside its LOQTORZI commercial ramp.

Coherus Oncology, Inc. Schedule 13G/A amendment shows the Timothy G. Youngquist 2020 Irrevocable Trust beneficially owns 12,790,800 shares of common stock, representing 8.267% of the class. The filing states this percentage is based on 154,217,609 shares outstanding as of April 16, 2026 and includes 500,000 shares underlying call options deemed outstanding for purposes of Rule 13d-3.

Coherus Oncology, Inc. ownership update: Thomas A. Satterfield, Jr. reports beneficial ownership of 6,930,000 shares, equal to 4.6% of the company's common stock. The filing cites 149,889,902 shares outstanding as of February 28, 2026 per the issuer's Form 10-K. The reported holdings combine sole and shared voting/dispositive power and include shares held jointly, by related entities (Tomsat Investment & Trading Co., Inc.; Caldwell Mill Opportunity Fund; A.G. Family L.P.) and multiple limited powers of attorney for other holders.

Coherus Oncology, Inc. amendment to a Schedule 13G/A reports that BlackRock, Inc. beneficially owned 7,337,261 shares of Common Stock, representing 4.9% of the class. The filing lists sole voting power of 7,232,734 shares and sole dispositive power of 7,337,261. The form is signed by a BlackRock Managing Director on 04/27/2026.

Coherus Oncology, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on director elections, auditor ratification, executive pay, a one-time stock option repricing and a larger equity incentive pool. Holders of 154,217,609 common shares as of April 16, 2026 may vote online or by proxy.

Stockholders will elect two Class III directors, ratify Ernst & Young LLP as independent auditor for 2026, and cast an advisory “say‑on‑pay” vote on named executive officer compensation. They are also being asked to approve reducing the exercise price and extending the term of 9,540,140 underwater employee and consultant options, and to add 7,700,000 shares to the Amended and Restated 2014 Equity Incentive Award Plan.

The board, which is majority independent and organized into audit, compensation, and nominating/governance committees, recommends voting “FOR” all five proposals, including the equity plan amendment intended to preserve stock‑based incentives as a core element of compensation and retention.

Coherus Oncology, Inc. filed preliminary proxy materials for its virtual 2026 Annual Meeting to be held on May 27, 2026. The Board asks stockholders to vote on election of directors, ratification of Ernst & Young as auditor, a non-binding say-on-pay, a one-time repricing of certain employee and consultant stock options covering 9,540,140 shares with exercise prices from $5.44 to $30.98, and a proposed 7,700,000-share increase to the 2014 Equity Incentive Award Plan reserve.

The repricing would reset Eligible Options to the closing price on the meeting date and extend option terms by ten years, but would restore original exercise prices if options are exercised or service terminates before May 27, 2027. The Board recommends a vote "FOR" all proposals.

Coherus Oncology Inc — The Vanguard Group filed Amendment No. 5 to Schedule 13G/A reporting 0 shares beneficially owned of Coherus Oncology common stock, representing 0% of the class. The filing includes a disclosure that Vanguard underwent an internal realignment on January 12, 2026 leading to disaggregated reporting. The form is signed by Ashley Grim, Head of Global Fund Administration on 03/26/2026.

Coherus Oncology, Inc. describes a strategic shift to become a fully integrated commercial-stage oncology company centered on its PD‑1 inhibitor LOQTORZI for nasopharyngeal carcinoma and a focused immuno-oncology pipeline.

LOQTORZI is FDA‑approved in the United States for first‑line metastatic or recurrent locally advanced nasopharyngeal carcinoma in combination with cisplatin and gemcitabine, and as monotherapy after platinum-based chemotherapy. The company estimates up to 2,000 recurrent or metastatic NPC patients in the United States are eligible, representing a $250 million market opportunity.

Coherus highlights mid‑stage clinical candidates casdozokitug (anti‑IL‑27) and tagmokitug (anti‑CCR8), both intended for combination use with LOQTORZI and partners’ agents across liver, head and neck, colorectal and other cancers. It reports multiple collaborations and licenses, including Junshi Biosciences, Apotex, Janssen, Adimab and Vaccinex.

The company notes completion of the divestiture of its UDENYCA biosimilar franchise in April 2025, reinforcing its oncology focus. As of June 30 2025, aggregate market value of common stock held by non‑affiliates was approximately $81.9 million, and shares outstanding were 149,889,902 as of February 28 2026.